On the surface, that sounds like a good idea.

There’s been recent discussion about screening military personnel for low testosterone.

If a young man truly has testosterone deficiency, identifying it and treating it appropriately could improve his health, quality of life, and readiness.

I don’t have a problem with that.

The question that interests me is what happens after the blood test.

Because a testosterone level, by itself, isn’t a diagnosis.

In urology, we don’t diagnose testosterone deficiency with a laboratory value alone.

We diagnose it with two things.

A consistently low testosterone level.

And symptoms that fit.

Both matter.

A healthy 25-year-old with a testosterone of 280 who feels well is a very different patient than a 25-year-old with the same number who has low libido, fatigue, reduced muscle mass, osteoporosis, or other signs of testosterone deficiency.

The number isn’t the diagnosis.

The man is.

It’s also worth asking what question we’re trying to answer.

Are we trying to identify men with an untreated medical condition?

Or are we hoping to make healthy young men perform better?

Those are very different goals, and they deserve different standards of evidence.

There is good evidence that testosterone replacement benefits men who truly have testosterone deficiency.

There is much less evidence that broadly screening healthy, asymptomatic young men—and treating laboratory values alone—improves long-term health or performance.

We’ve talked before about testosterone replacement being a safe and effective treatment when it’s prescribed for the right patient and monitored appropriately.

But it isn’t a harmless vitamin.

In younger men, testosterone therapy commonly suppresses sperm production, affects testicular function, and can reduce fertility while treatment continues. 

Coming off therapy isn’t always straightforward, and recovery of the body’s own testosterone production can take time.

Those conversations matter much more at 25 than they do at 65.

The other part of this discussion is monitoring.

Writing a prescription is easy.

Following someone over time is the hard part.

Military medicine has always understood that.

When I cared for servicemen with testicular cancer, treatment decisions sometimes changed if deployment meant years of careful surveillance weren’t realistic. 

In some situations, we chose a more aggressive treatment up front because it substantially lowered the chance of recurrence in someone who might not be available for close follow-up.

Different disease.

Same principle.

Treatments that require ongoing monitoring deserve ongoing monitoring.

Would there be value in knowing a young man’s baseline testosterone?

Perhaps.

It’s an interesting idea.

But even that isn’t as straightforward as it sounds.

Testosterone varies throughout the day, which is why we usually measure it in the morning.

Levels fluctuate from one test to another, and an unexpectedly low result should usually be confirmed before anyone reaches for a prescription.

A screening program needs a plan for what happens after the blood draw—not just during it.

If broader testing helps identify young men with genuine testosterone deficiency who might otherwise have been missed, that’s a win.

If it convinces healthy young men that a laboratory number alone means they need lifelong hormone therapy, that’s a very different outcome.

Medicine has always been about treating patients.

Not laboratory values.

As testosterone becomes a bigger part of the public conversation, that’s a distinction I hope we don’t lose.